Cvfg LLC Buys New Stake in argenex SE $ARGX

Cvfg LLC bought a new position in argenex SE (NASDAQ:ARGX) during the 1st quarter, Holdings Channel reports. The fund bought 8,517 shares of the company’s stock, valued at approximately $6,220,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital World Investors grew its position in shares of argenex by 0.4% in the third quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after purchasing an additional 8,422 shares during the last quarter. M&T Bank Corp lifted its position in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Wellington Management Group LLP boosted its stake in argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares during the period. Morgan Stanley boosted its stake in argenex by 19.2% during the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after purchasing an additional 83,746 shares during the period. Finally, Invesco Ltd. grew its holdings in argenex by 390.4% in the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after buying an additional 331,489 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. Royal Bank Of Canada lifted their price target on argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a research report on Tuesday. Bank of America raised their price objective on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Morgan Stanley upped their target price on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Finally, Oppenheimer reduced their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and an average price target of $1,037.61.

argenex Trading Up 0.3%

Shares of ARGX stock opened at $919.94 on Wednesday. argenex SE has a 12 month low of $536.02 and a 12 month high of $953.58. The company has a market capitalization of $57.21 billion, a P/E ratio of 40.96, a P/E/G ratio of 1.13 and a beta of 0.45. The stock has a 50 day moving average of $846.35 and a two-hundred day moving average of $811.75.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. Sell-side analysts predict that argenex SE will post 26.27 earnings per share for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.